ZIVO Bioscience, Inc. (ZIVO)
OTCMKTS
· Delayed Price · Currency is USD
19.00
+0.17 (0.90%)
Dec 20, 2024, 4:00 PM EST
ZIVO Bioscience Employees
ZIVO Bioscience had 8 employees as of December 31, 2023. The number of employees did not change compared to the previous year.
Employees
8
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$9,878
Profits / Employee
-$1,711,500
Market Cap
67.38M
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Sandoz Group AG | 22,633 |
| Telix Pharmaceuticals Limited | 234 |
| Elekta AB (publ) | 4,718 |
| Ryman Healthcare Limited | 7,700 |
| Verano Holdings Corp. | 3,900 |
| Vireo Growth Inc. | 490 |
| Medexus Pharmaceuticals Inc. | 82 |
ZIVO Bioscience News
- 1 day ago - ZIVO Bioscience Reports Preliminary Efficacy of its Proprietary Active Ingredients in the Battle Against Avian Influenza - Business Wire
- 4 months ago - Director and 10% Owner Christopher Maggiore Acquires 31,336 Shares of Zivo Bioscience Inc (ZIVO) - GuruFocus
- 4 months ago - ZIVO Reports Favorable Results from 42-Day Confirmatory Study of its Coccidiosis Treatment in Broiler Chickens - Business Wire
- 5 months ago - Major Global Animal Health Company Launches 42-Day Confirmatory Study with ZIVO Bioscience's Coccidiosis Treatment in Broiler Chickens - Business Wire
- 11 months ago - ZIVO Bioscience Reports Additional Findings from Positive 42-Day Coccidiosis Challenge Study - Business Wire
- 11 months ago - ZIVO Bioscience Announces Uplisting to OTCQB Market - Business Wire
- 11 months ago - ZIVO Bioscience Reports Positive Efficacy Results from 42-Day Validation Study with Non-Antibiotic Immune-Modulating Product for the Prevention and Treatment of Coccidiosis in Broiler Chickens - Business Wire
- 1 year ago - ZIVO Bioscience Initiates 42-Day Validation Study with Immune-Modulating Product for the Prevention and Treatment of Coccidiosis in Broiler Chickens - Business Wire